Kathleen D. Schaum has been added to the biographical volumes of Marquis Who’s Who. She is a founding member of Today’s Wound Clinic and frequent author of TWC’s Business Briefs and Consultation Corner columns, as well as the founder and presenter of Wound Clinic Business.
After seeing numerous talented medical professionals who lacked skill in the business aspect of the field, Ms. Schaum decided to pursue a career in the field, culminating in her current role as the founder and president of Kathleen D. Schaum and Associates Inc., which provides strategic reimbursement consultation and education for wound/ulcer management manufacturers and providers, according to a press release. As part of the responsibilities of her role, she consults with new and established hospital outpatient wound and ulcer management departments, physicians, podiatrists, nurse practitioners, wound nurses and more.
Ms. Schaum also consistently monitors reimbursement legislation and regulations, attends reimbursement meetings and seminars and parlays that knowledge to her clients and various audiences in a digestible format, notes the press release. Over the years, she has led reimbursement strategies for more than 100 manufacturers, received Medicare billing codes for more than 400 wound/ulcer management products and provided executive reimbursement workshops for senior executives and reimbursement training for more than 4,000 sales and marketing representatives.
Within the next five years, Ms. Schaum aims to provide more virtual webinars and in-person reimbursement educational programs in the field and parlay her expertise in reimbursement to the general population, notes the press release.
For more info, go to www.24-7pressrelease.com/press-release-service/474656 .
MolecuLight i:X® Platform Now Available on Epic’s App Orchard
MolecuLight Inc., the leader in point-of-care fluorescence imaging for real-time detection of bacteria in wounds, announces the availability of its MolecuLight i:X® platform on the Epic App Orchard Marketplace and the integration of its platform with Epic’s leading electronic medical record (EMR) platform. The app is known as iX Imaging.
Practitioners who use Epic for the treatment of wounds can upload standard and fluorescence images, and measurements captured with the MolecuLight i:X device at the point-of-care to the patient’s record, according to the company. The integrated platforms allow clinicians to optimize their workflow and document their patients’ wounds digitally.
For more info, go to https://us.moleculight.com/ .
Sensoria Includes Wellness Coach in IoT Smart Cushion for Wheelchair Users
Sensoria Health announced it completed development of the first internet of things (IoT)-connected, comfortable and artificial intelligence (AI)-enabled cushion and software system designed for wheelchair users to reduce risk of ulceration.
The fully functional smart cushion and mobile app prototype is currently being tested at Rancho Los Amigos National Rehabilitation Center in Los Angeles, according to Sensoria. Studies have shown that in-seat movement is the cornerstone of pressure injury prevention for any wheelchair user. The company notes the new textile pressure sensor infused Sensoria® Mat AI algorithms and mobile app coach users when to change position and monitor how often and how well users execute pressure relief activities.
For more info, go to www.sensoriahealth.com/sensoria-mat/.
Reapplix Receives New Reimbursement Coding for DFU Therapy
Reapplix has successfully received Medicare reimbursement coding instructions from the Centers for Medicare and Medicaid Services (CMS) with a national average payment rate of $1,622.74. The rate covers each patient visit to hospital outpatient departments to receive 3C Patch® therapy for hard-to-heal diabetic foot ulcers, notes the company.
The reimbursement coding instructions received from CMS were provided under the Coverage with Evidence Development (CED) framework, notes Reapplix. In parallel, the company says CMS has reopened its National Coverage Analysis (NCA) process for Autologous Blood-Derived Products for Chronic Non-Healing Wounds with a stated, expected NCA completion date of January 2021. Reapplix expects that the CED framework arrangement will be replaced by a positive National Coverage Determination decision with a permanent future coding and reimbursement rate at the beginning of 2021.
For more info, go to https://reapplix.com/reapplix-receives-new-reimbursement-coding-and-completes-usd-22-6m-equity-financing-to-drive-us-commercialization/ .